Lazard Asset Management
TGTX icon

Lazard Asset Management’s TG Therapeutics TGTX Stock Holding History

Lazard Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,027
Closed -$72K – 2304
2025
Q2 		$72K Sell
2,027
-4,454
-69% -$166K ﹤0.01% 1942
2025
Q1 		$254K Buy
6,481
+105
+2% +$3.53K ﹤0.01% 1570
2024
Q4 		$191K Sell
6,376
-2,977
-32% -$85.4K ﹤0.01% 1623
2024
Q3 		$218K Buy
9,353
+89
+1% +$1.94K ﹤0.01% 1590
2024
Q2 		$163K Buy
9,264
+3,191
+53% +$50.9K ﹤0.01% 1623
2024
Q1 		$91K Buy
+6,073
New +$96.7K ﹤0.01% 1568
2023
Q4 		– Sell
-6,736
Closed -$56K – 2464
2023
Q3 		$56K Buy
+6,736
New +$93.9K ﹤0.01% 1826
2022
Q3 		– Sell
-6,327
Closed -$26K – 2550
2022
Q2 		$26K Hold
6,327
– – ﹤0.01% 2063
2022
Q1 		$60K Buy
+6,327
New +$73.2K ﹤0.01% 1653
2021
Q4 		– Sell
-19,444
Closed -$647K – 2458
2021
Q3 		$647K Buy
+19,444
New +$602K ﹤0.01% 1135

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Lazard Asset Management's TGTX Position: Q3 2025 in Review

Lazard Asset Management sold out of TG Therapeutics (TGTX) in Q3 2025, closing a stake of 2,027 shares — an estimated $72K sold.

Lazard Asset Management first reported a position in TGTX in Q3 2021 and held it in 10 quarters. The position peaked at $647K in Q3 2021. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

  • Lazard Asset Management reported no remaining TG Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 2,027 TG Therapeutics shares in Q3 2025, an estimated $72K.
  • Lazard Asset Management first reported a position in TG Therapeutics in Q3 2021 and held it in 10 quarters.
  • Lazard Asset Management's TG Therapeutics position peaked at $647K in Q3 2021.
  • 354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.